Search

Displaying results 1751 - 1760 of 3735 in total
  1. Drug

    Zalifrelimab

    go.drugbank.com/drugs/DB15632
    Investigational

    Zalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).

  2. Drug

    PF-5212372

    go.drugbank.com/drugs/DB19212
    Investigational

    PF-5212372 is under investigation in clinical trial NCT02795832 (A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis).

  3. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    Treatment options for patients with FOP are extremely limited, although there has been substantial recent interest in novel treatments for this disease. … [A244920] Palovarotene is a selective agonist of retinoic acid receptor gamma (RARγ) belonging to a class of medications known as retinoids, similar in mechanism to drugs like [tazarotene] or [trifarotene

    Categories: Retinoic Acid Receptor gamma, agonists, Cytochrome P-450 Substrates
  4. Drug

    Florzolotau F-18

    go.drugbank.com/drugs/DB16297
    Investigational

    PMPBB3 F-18 is under investigation in clinical trial NCT04305210 (Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18f-florbetapir (AV-45) PET Examination).

  5. Drug

    Montelukast

    go.drugbank.com/drugs/DB00471
    ApprovedInvestigational

    although these kinds of effects are currently included in the official prescribing information for montelukast,[L6301,L6304,L6307,L6310,L6325,L6328,L6331] the drug still sees extensive use worldwide via … [L6301] The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersProducts: MONK-P
  6. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United ...

  7. Target

    Kainate receptors

    go.drugbank.com/bio_entities/BE0009793
    TargetHumans

    The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist … Ionotropic glutamate receptor that functions as a cation-permeable ligand-gated ion channel, gated by L-glutamate and the glutamatergic agonist kainic acid.

    Polypeptides: Glutamate receptor ionotropic, kainate 1, Glutamate receptor ionotropic, kainate 2Synonyms: Glutamate receptor 5, Glutamate receptor 6
  8. Drug

    RG2417

    go.drugbank.com/drugs/DB05055
    Investigational

    Recent reports indicate that certain genes that encode for mitochondrial proteins are significantly down regulated in the brains of bipolar patients.

  9. Drug

    Zinc sulfate, unspecified form

    go.drugbank.com/drugs/DB14548
    Approved

    Zinc sulfate is a common zinc supplement in parenteral nutrition.

    Mixtures: Se-Tan PLUS
  10. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. … [A180478] As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in

    Categories: Interleukin-4 Receptor alpha Antagonist, Interleukin 4 Receptor alpha Antagonists